Journey from Aquarium-to-Bedside to Treat Genetic Epilepsies

Emerging from stealth mode with a pipeline of FDA and EMA Orphan Drug Designation candidates, Epygenix Therapeutics Inc. is poised to become the first biopharmaceutical company to commercialize epilepsy drugs discovered in zebrafish. Epygenix Therapeutics’ six lead drug candidates were identified in a high-throughput phenotype-based drug screening system using a unique zebrafish model developed in the laboratory of Professor Scott C. Baraban, PhD at the University of California, San Francisco (UCSF).